Lavigne, Pierre

Professeur, Faculté de médecine et des sciences de la santé
FMSS Dép. de biochimie et de génomique fonction.

Coordonnées

Courriel


819-821-8000, poste 75462

Diplômes

(1998) Post-doctorate (Other). University of Alberta.

(1994) Doctorate (Doctor of Philosophy). Université du Québec à Trois-Rivières.

(1989) Bachelor's (Bachelor of Science). Université du Québec à Trois-Rivières.

Présentation

Sujets de recherche

Macromolecules, Modelization and Simulation, Molecular Structure and Sizing, Oncogenes, Thermodynamic Properties.

Disciplines de recherche

Biochemistry, Pharmacology.

Mots-clés

Cancer Biology, CD Spectroscopy, Molecular Recognition, NMR Spectroscopy, Protein Engineering, Protein Structure, Structural Biology, Thermodynamics, Transcription, Transcription Factors.

Intérêts de recherche

1- Development of c-Myc inhibitors, 2- Structural biology of Miz-1, 3-Structural biology of START domains, 4- Structural biology of GPCRs and 5- Structural biology of pro-Urotensin-II.

Centres de recherche

Centre de recherche du CHUS, Groupe de recherche axé sur la structure des protéines (GRASP), None.

Langues parlées et écrites

Anglais, Français

Publications

Articles de revue

  • Li X, Lavigne P, Lavoie C. (2015). *GGA3 Mediates TrkA Endocytic Recycling to PromoteSustained Akt Phosphorylation and Cell Survival. Mol Biol Cell., (In Press).
  • Domazet I, Holleran BJ, Richard A, Vandenberghe C, Lavigne P, Escher E, Leduc R, Guillemette G. (2015). *Characterization of Angiotensin II Molecular Determinants Involved in AT1 Receptor Functional Selectivity. Mol Pharmacol., 87(6), 982-95. (Published).
  • Cabana J, Holleran B, Leduc R, Escher E, Guillemette G, Lavigne P. (2015). *Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations. J. Biol. Chem., 290(25), 15835-15854. (Published).
  • Létourneau D, Lefebvre A, Lavigne P, LeHoux JG. (2015). *The binding site specificity of STARD4 subfamily: Breaking the cholesterol paradigm. Mol. Cell Endocrinol., 408, 53-61. (Published).
  • Sainsily X, Cabana J, Holeran B J, Escher E, Lavigne P, Leduc R. (2014). *Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochem. Pharmacol., 86, 1584-93. (Published).
  • Béland M , Bédard M , Tremblay G , Lavigne P , Roucou X. (2014). *Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates. Neurobiology of aging, 35(7), 1537-48. (Published).
  • Sainsily X , Cabana J , Boulais PE , Holleran BJ , Escher E , Lavigne P , Leduc R. (2013). *Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochem. Pharmacol., 86(11), 1584-93. (Published).
  • Létourneau D , Lorin A , Lefebvre A , Cabana J , Lavigne P , LeHoux JG. (2013). *Thermodynamic and solution state NMR characterization of the binding of secondary and conjugated bile acids to STARD5. Biochimica et biophysica acta, 1831(11), 1589-99. (Published).
  • Bernard D , Bédard M , Bilodeau J , Lavigne P. (2013). Structural and dynamical characterization of the Miz-1 zinc fingers 5-8 by solution-state NMR. Journal of biomolecular NMR, 57, 103-116. (Published).
  • Lorin A , Létourneau D , Lefebvre A , LeHoux JG , Lavigne P. (2013). *(1)H, (13)C, and (15)N backbone chemical shift assignments of StAR-related lipid transfer domain protein 5 (STARD5). Biomolecular NMR assignments, 7(1), 21-4. (Published).
  • Fillion D , Cabana J , Guillemette G , Leduc R , Lavigne P , Escher E. (2013). *Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode. The Journal of biological chemistry, 288(12), 8187-97. (Published).
  • Cabana J , Holleran B , Beaulieu MÈ , Leduc R , Escher E , Guillemette G , Lavigne P. (2013). *Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor. The Journal of biological chemistry, 288(4), 2593-604. (Published).
  • Létourneau D , Lefebvre A , Lavigne P , Lehoux JG. (2013). *STARD5 specific ligand binding: Comparison with STARD1 and STARD4 subfamilies. Molecular and cellular endocrinology, 371, 20-25. (Published).
  • Létourneau D , Lorin A , Lefebvre A , Frappier V , Gaudreault F , Najmanovich R , Lavigne P , LeHoux JG. (2012). *StAR-related lipid transfer domain protein 5 binds primary bile acids. Journal of lipid research, 53(12), 2677-89. (Published).
  • Bédard M , Maltais L , Beaulieu ME , Bilodeau J , Bernard D , Lavigne P. (2012). NMR structure note: solution structure of human Miz-1 zinc fingers 8 to 10. Journal of biomolecular NMR, 54(3), 317-23. (Published).
  • Beaulieu ME , McDuff FO , Frappier V , Montagne M , Naud JF , Lavigne P. (2012). New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ. Journal of molecular recognition : JMR, 25(7), 414-26. (Published).
  • Lorin A , Létourneau D , Lefebvre A , Lehoux JG , Lavigne P. (2012). *(1)H, (13)C, and (15)N backbone chemical shift assignments of StAR-related lipid transfer domain protein 5 (STARD5). Biomolecular NMR assignments, 7, 21-24. (Accepted).
  • Montagne M , Beaudoin N , Fortin D , Lavoie CL , Klinck R , Lavigne P. (2012). *The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities. PLOS one, 7(2), e32172. (Published).
  • Lefrançois M , Lefebvre MR , Saint-Onge G , Boulais PE , Lamothe S , Leduc R , Lavigne P , Heveker N , Escher E. (2011). *Agonists for the Chemokine Receptor CXCR4. ACS medicinal chemistry letters, 2(8), 597-602. (Published).
  • Bilodeau J , Désilets A , McDuff FO , St-Pierre C , Barbar E , Leduc R , Lavigne P. (2011). *Influence of Ca2+ and pH on the folding of the prourotensin II precursor. FEBS letters, 585(12), 1910-4. (Published).
  • Arsenault J , Cabana J , Fillion D , Leduc R , Guillemette G , Lavigne P , Escher E. (2010). *Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism. Biochem. Pharmacol., 80(7), 990-9. (Published).
  • Arsenault J , Lehoux J , Lanthier L , Cabana J , Guillemette G , Lavigne P , Leduc R , Escher E. (2010). *A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity. Pharmacogenetics and genomics, 20(6), 377-388. (Published).
  • Fillion D , Lemieux G , Basambombo LL , Lavigne P , Guillemette G , Leduc R , Escher E. (2010). *The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. Journal of medicinal chemistry, 53(5), 2063-75. (Published).

Chapitres de livre

  • D. Létourneau, P. Lavigne, A. Lefebvre, J.-G. LeHoux. (2014). *START Domain Protein Structure and Ligand Specificity. Cholesterol Transporters of the START Domain Protein Family in Health and Disease (49-72). Springer Science. (Published).
  • M.-E. Beaulieu, F.-O. Mc Duff, M. Bédard, M. Montagne and P. Lavigne. (2013). Methods for the expression, purification, preparation and biophysical characterization of constructs of the c-Myc and Max b-HLH-LZs. Methods in Molecular Biology (7-20). Springer Science. (Published).

Autres contributions

Présentations

  • (2015). The structural biology of the Myc/Max/Mad/Miz1 network of transcription factors. Invited Lecture. Vancouver.
  • (2014). Structural Biology of the Myc/Max/Mad/Miz1 network of transcription factors and the development of Myc inhibitors. Department of Biochemistry and Molecular Biology, University of Louisville. Louisville.
  • (2014). Design of b-HLH-LZ domains that can inhibit c-Myc in vitro and in vivo. Syros Pharmaceuticals. Boston.
  • (2014). Ligand Diversity and Binding Mechanism of START Domains from the STARD4 Subfamily. Adrenal 2014. Chicago.
  • (2012). Structural Biology of the c-Myc/Max/Mad/Miz1 network: Toward the development of c-Myc inhibitors. Department of Biochemistry, University of Cambridge. Cambridge.
  • (2012). Towards the solution NMR structure of STARD6 and the discovery of new ligands of STARD5. Department of Molecular Biology and Biochemistry, Dalhousie University. Halifax.